Atigliflozin | 647834-15-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Atigliflozin
• 英文别名: (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[2-[(4-methoxyphenyl)methyl]thiophen-3-yl]oxyoxane-3,4,5-triol
• CAS: 647834-15-9
• 化学式: C₁₈H₂₂O₇S
• 分子量: 382.434
• InChiKey: BUXGTLNOWLNUKF-SOVHRIKKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  137
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  Atigliflozin 在 吡啶 、 4-二甲氨基吡啶 、 sodium methylate 、 戴斯-马丁氧化剂 、 氟化氢吡啶 作用下， 生成 3-(2-(4-methoxybenzyl)-thiophenyl)-β-D-glucuronide
  参考文献：
  名称：

  选定的 II 期代谢物的合成 - 药物开发候选物的 Ο-葡糖苷酸和硫酸盐

  摘要：

  我们总结了 II 期代谢物的制备方法，这些方法在我们的实验室中被证明是成功的，用于合成近期候选药物的选定 O-葡糖苷酸和硫酸盐。O-葡糖苷酸AVE0897 O-酰基葡糖苷酸7、AVE2268 O-葡糖苷酸12、SAR7226 O-葡糖苷酸21的合成以及AVE2268和MDL107292 33的硫酸盐28的制备被详细描述。讨论了与 II 相代谢物相关的分析方面和强极性化合物的特定色谱方法。

  DOI：

  10.3998/ark.5550190.0013.319
• 作为产物：
  描述：

  2-{2-[hydroxy-(4-methoxy-phenyl)-methyl]-thiophen-3-yloxy}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol 生成 Atigliflozin
  参考文献：
  名称：

  Thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof

  摘要：

  本发明揭示了公式I的新型噻吩糖苷衍生物及其生理上可耐受的盐和制备它们的方法。其中，基团具有所述的含义。该化合物可用作抗糖尿病药物。

  公开号：

  US07666848B2

文献信息

• [EN] MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO<br/>[FR] MODULATEURS DU RÉCEPTEUR GPR119 ET TRAITEMENT DES TROUBLES QUI LUI SONT LIÉS
  申请人：ARENA PHARM INC

  公开号：WO2012040279A1

  公开（公告）日：2012-03-29

  The present invention relates to the GPR119 receptor agonists:3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)-N,N-dimethylbenzamide; -fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)-N-methylbenzamide; and 3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)benzamide, and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as a single pharmaceutical agent or in combination with one or more additional pharmaceutical agents, such as, a DPP-IV inhibitor, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, or an anti-diabetic peptide analogue, in the treatment of, for example, a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing secretion of an incretin; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.

  本发明涉及GPR119受体激动剂：3-氟-4-(5-氟-6-(4-(3-(2-氟丙基)-1,2,4-噁二唑-5-基)哌啶-1-基)嘧啶-4-基氨基)-N,N-二甲基苯甲酰胺；-氟-4-(5-氟-6-(4-(3-(2-氟丙基)-1,2,4-噁二唑-5-基)哌啶-1-基)嘧啶-4-基氨基)-N-甲基苯甲酰胺；以及3-氟-4-(5-氟-6-(4-(3-(2-氟丙基)-1,2,4-噁二唑-5-基)哌啶-1-基)嘧啶-4-基氨基)苯甲酰胺，以及其药学上可接受的盐、溶剂化合物和水合物，这些化合物可用作单一药物代理或与一个或多个额外的药物代理结合使用，例如DPP-IV抑制剂、双胍类药物、α-葡萄糖苷酶抑制剂、胰岛素类似物、磺脲类药物、SGLT2抑制剂、噻唑烷二酮类药物或抗糖尿病肽类似物，用于治疗例如从以下选择的疾病：GPR119受体相关疾病；通过增加胰高血糖素分泌而改善的疾病；通过增加血液中胰高血糖素水平而改善的疾病；低骨密度症状；神经系统疾病；代谢相关疾病；2型糖尿病；肥胖症；以及相关并发症的治疗。
• [EN] MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO<br/>[FR] MODULATEURS DU RÉCEPTEUR GPR119 ET TRAITEMENT DE TROUBLES ASSOCIÉS
  申请人：ARENA PHARM INC

  公开号：WO2013055910A1

  公开（公告）日：2013-04-18

  The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof,that are useful as single pharmaceutical agents or in combination with one or more additional pharmaceutical agents, such as, an inhibitor of DPP-IV, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, or an anti-diabetic peptide analogue, in the treatment of, for example, a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing secretion of an incretin; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.

  本发明涉及式(I)的化合物及其药学上可接受的盐、溶剂化合物、水合物和N-氧化物，这些化合物可作为单一药物代理或与一个或多个额外的药物代理结合使用，例如DPP-IV的抑制剂、双胍类药物、α-葡萄糖苷酶抑制剂、胰岛素类似物、磺脲类药物、SGLT2抑制剂、噻嗪二酮类药物或抗糖尿病肽类似物，用于治疗例如从以下选择的疾病中选择的疾病：GPR119受体相关疾病；通过增加促胰高血糖素分泌而改善的状况；通过增加血液促胰高血糖素水平而改善的状况；低骨量状况；神经系统疾病；与代谢相关的疾病；2型糖尿病；肥胖症；以及相关并发症。
• [EN] MODULATORS OF GPR119 AND THE TREATMENT OF DISORDERS RELATED THERETO<br/>[FR] MODULATEURS DE GPR119 ET TRAITEMENT DE TROUBLES ASSOCIÉS À CEUX-CI
  申请人：ARENA PHARM INC

  公开号：WO2014074668A1

  公开（公告）日：2014-05-15

  The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts, solvates, and hydrates thereof, Formula (I), that are useful as single pharmaceutical agents or in combination with one or more additional pharmaceutical agents, such as, an inhibitor of DPP-IV, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, an anti-diabetic peptide analogue, or a DGAT-1 inhibitor, in the treatment of, for example, a disorder selected from: a GPR119-related disorder; a condition ameliorated by increasing secretion of an incretin; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.

  本发明涉及化合物的公式(I)及其药学上可接受的盐、溶剂化合物和水合物，公式(I)可作为单一药物代理或与一个或多个其他药物代理结合使用，例如DPP-IV抑制剂、双胍类药物、α-葡萄糖苷酶抑制剂、胰岛素类似物、磺脲类药物、SGLT2抑制剂、胰岛素分泌促进剂、噻唑烷二酮类药物、抗糖尿病肽类似物或DGAT-1抑制剂，用于治疗例如GPR119相关疾病；通过增加内分泌物分泌改善的疾病；通过增加血液内分泌物水平改善的疾病；低骨量疾病；神经系统疾病；与代谢相关的疾病；2型糖尿病；肥胖及相关并发症。
• THERAPEUTIC USES OF SGLT2 INHIBITORS
  申请人：Seed Brian

  公开号：US20110077212A1

  公开（公告）日：2011-03-31

  Provided are methods of using one or more SGLT2 inhibitors, independently or in combination, for treating edema or reducing fluid retention. The invention also provides methods of using one or more SGLT2 inhibitors for the preparation of a medicament for treating edema or fluid retention. Methods are also provided for treating diabetes with an amount of one or more SGLT2 inhibitors and one or more PPAR-gamma agonists.

  提供了使用一种或多种SGLT2抑制剂的方法，独立使用或结合使用，用于治疗水肿或减少液体潴留。本发明还提供了使用一种或多种SGLT2抑制剂制备治疗水肿或液体潴留药物的方法。还提供了使用一种或多种SGLT2抑制剂和一种或多种PPAR-γ激动剂治疗糖尿病的方法。
• Thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：US07666848B2

  公开（公告）日：2010-02-23

  Novel thiophene glycoside derivatives of the formula I in which the radicals have the stated meanings, and the physiologically tolerated salts thereof and processes for their preparation are disclosed. The compounds are suitable, for example, as antidiabetics.

  本发明揭示了公式I的新型噻吩糖苷衍生物及其生理上可耐受的盐和制备它们的方法。其中，基团具有所述的含义。该化合物可用作抗糖尿病药物。